Evidence of Nitric Oxide-Cyclic GMP-Potassium Channels Involvement in Antinociceptive Activity of Chalcone Derivative; 3-(2,5-dimethoxy phenyl)-1-(5-methyl furan-2-yl) prop-2-en-1 (DMPF-1) Using Behaviour-Induced Nociception http://www.doi.org/10.26538/tjnpr/v7i8.25
Article Sidebar
Main Article Content
Abstract
Chalcones are interesting and versatile compounds due to their various pharmacological properties. Important biological activities of chalcones have been reported for decades using different experimented models. The 3-(2,5-dimethoxy phenyl)-1-(5-methyl furan-2-yl) prop-2-en- 1 (DMPF-1) is one of the chalcone analogues that has reported to have analgesic properties despite of it published safety profile. The present study examined the possible anti nociceptive modulatory activity exerted by the DMPF-1 compound in behavioural-induced nociception in animal model using Institute of Cancer Research (ICR) mice. Administration of DMPF-1 compound at a dose
of 1 mg/kg intraperitoneally exerted a pronounced antinociceptive effect against acetic acidinduced nociception. The antinociceptive effect of the DMPF-1 compound significantly (P<0.001) was reversed by the pre-treatment of the animals with the nitric oxide precursor; L-arginine (100mg/kg; i.p), and the soluble guanylyl cyclase inhibitor; oxadiazole (4,3-a) quinoxaline-1-one (ODQ) (2.0 mg/kg; i.p.). A similar inhibitory pattern was observed upon the challenge of DMPF- 1 against two potassium channel inhibitors, glibenclamide (10 mg/kg; i.p.) and tetraethylammonium (4 mg/kg; i.p.). Overall, these findings suggest the possible contribution of
nitric oxide-cyclic GMP-potassium signalling pathway in the antinociceptive activity exhibited by the DMPF-1 compound. This chalcone analogue and its molecular structure might be further investigated as a model that could be used to obtain more potent analgesic agents.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Chavan BB, Gadekar AS, Mehta PP, Vawhal PK, Kolsure A K, Chabukswar AR. Synthesis & Medicinal Significance of Chalcones-A Review. Asian J. Biomed. Pharm. Sci. 2016; 1 ;6(56):01-07.
Atukuri D, Vijayalaxmi S, Sanjeevamurthy R, Vidya L, Pras annakumar R, Raghavendra MM. Identification of quinoline -chalcones and heterocyclic chalcone-appended quinolines a s broad-spectrum pharmacological agents. Bioorg. Chem. 2020; 1;105:104419.
Gao F, Huang G, Xiao J. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure‐activity relationship. Med. Res. Rev. 2020; 40(5) :2049-84.
Pasricha S, Gahlot P. Synthetic Strategies and Biological Potential of Coumarin-Chalcone Hybrids: A New Dimension to Drug Design. Curr. Org. Chem. 2020; 1;24(4):402-38.
Rajajendram R, Tham CL, Akhtar MN, Sulaiman MR, Israf DA. Inhibition of epithelial CC-family chemokine synthesis by the synthetic chalcone DMPF-1 via disruption of NF-κB nuclear translocation and suppression of experimental asthma in mice. Mediators inflamm. 2015; 2;2015.
Bakar NA, Sulaiman MR, Lajis N, Akhtar MN, Mohamad AS. Evaluation of Antinociceptive Profile of Chalcone Derivative (3-(2, 5-dimethoxyphenyl)-1-(5-methylfuran-2-yl) prop-2-en-1-one (DMPF-1) in vivo. J Pharm Bioallied Sci. 2020; 12(Suppl 2):S711.
Bakar NA, Suliman NA, Sulaiman MR, Akhtar N. Acute And Subacute Toxicity Profile Of (3-(2, 5-Dimethoxyphenyl)-1 -(5-Methylfuran-2-Yl) Prop-2-En-1-One, Chalcone Derivative In Experimental Animal Model. Malays Appl Biol. 2021; 30;50(2):9-18.
Gühring H, Tegeder I, Lötsch J, Pahl A, Werner U, Reeh PW, Rehse K, Brune K, Geisslinger G. Role of nitric oxide in zymosan induced paw inflammation and thermal hyperalgesia. J. Inflamm. Res. 2001; 50:83-8.
Ali EM, Soha HM, Mohamed TM. Nitric oxide synthase and oxidative stress: Regulation of nitric oxide synthase. Oxidative stress-molecular mechanisms and biological effects. InTech. 2012; 25:61-72.
Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu. Rev. Biochem. 1994; 63(1):175-95.
Kim DH, Li H, Han YE, Jeong JH, Lee HJ, Ryu JH. Modulation of inducible nitric oxide synthase expression in LPS-Stimulated BV-2 microglia by prenylated chalcones from Cullen corylifolium (L.) Medik. through inhibition of I-κBα degradation. Molecules. 2018 Jan 4;23(1):109.
Faudzi SM, Abdullah MA, Manap MR, Ismail AZ, Rullah K, Aluwi MF, Ramli AN, Abas F, Lajis NH. Inhibition of nitric oxide and prostaglandin E2 production by pyrrolylated-chalcones: Synthesis, biological activity, crystal structure analysis, and molecular docking studies. Bioorg. Chem. 2020 ;94:103376.
Rojas J, Domınguez JN, Charris JE, Lobo G, Payá M, Ferrá ́ndiz ML. Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase. Eur. J. Med. Chem. 2002 ;37(8):699-705.
Rojas J, Paya M, Dominguez JN, Ferrandiz ML. The synthesis and effect of fluorinated chalcone derivatives on nitric oxide production. Bioorganic Med. Chem. Lett. 2002; 5;12(15):1951-4.
Mittal A, Vashistha VK, Das DK. Recent advances in the antioxidant activity and mechanisms of chalcone derivatives: A computational review. Free Radic. Res. 2022; 3;56(5-6):378-97.
El-Sherief HA, Abuo-Rahma GE, Shoman ME, Beshr EA, Abdel-baky RM. Design and synthesis of new coumarin–chalcone/NO hybrids of potential biological activity. Med Chem Res. 2017; 26:3077-90.
Yang Y, Wei Z, Teichmann AT, Wieland FH, Wang A, Lei X, Zhu Y, Yin J, Fan T, Zhou L, Wang C. Development of a novel nitric oxide (NO) production inhibitor with potential therapeutic effect on chronic inflammation. Eur. J. Med. Chem. 2020 ;193:112216.
Emam SH, Sonousi A, Osman EO, Hwang D, Kim GD, Hassan RA. Design and synthesis of methoxyphenyl-and coumarin-based chalcone derivatives as anti-inflammatory agents by inhibition of NO production and down-regulation of NF-κB in LPS-induced RAW264. 7 macrophage cells. Bioorg Chem. 2021; 107:104630.
Minhas R, Bansal Y, Bansal G. Inducible nitric oxide synthase inhibitors: A comprehensive update. Med. Res. Rev. 2020; 40(3):823-55.
Liu L, Yang T, Bruno MJ, Andersen OS, Simon SA. Voltage-gated ion channels in nociceptors: modulation by cGMP. J. Neurophysiol. 2004; 92(4):2323-32.
Koster R, Anderson M, De Beer E. Acetic acid-induced analgesic screening. Fred. Proc. 1959.
Zakaria ZA, Roosli RA, Marmaya NH, Omar MH, Basir R, Somchit MN. Methanol extract of Dicranopteris linearis leaves attenuate pain via the modulation of opioid/NO-mediated pathway. Biomolecules. 2020 Feb; 10(2):280.
Ferdous A, Janta RA, Arpa RN, Afroze M, Khan M, Moniruzzaman M. The leaves of Bougainvillea spectabilis suppressed inflammation and nociception in vivo through the modulation of glutamatergic, cGMP, and ATP-sensitive K+channel pathways. J. Ethnopharmacol. 2020; 261:113148.
Collado-Alsina A, Rampérez A, Sánchez-Prieto J, Torres M. Nitric Oxide and Synaptic Transmission in the Cerebellum . In Handbook of the Cerebellum and Cerebellar Disorders 2021; (pp. 1025-1046). Cham: Springer International Publishing.
Cury Y, Picolo G, Gutierrez VP, Ferreira SH. Pain and analgesia: The dual effect of nitric oxide in the nociceptive system. Nitric oxide. 2011 Oct 30;25(3):243-54.
Liew CY, Lam KW, Kim MK, Harith HH, Tham CL, Cheah YK, Sulaiman MR, Lajis NH, Israf DA. Effects of 3-(2-Hydroxyphenyl)-1-(5-methyl-furan-2-yl) propenone (HMP) upon signalling pathways of lipopolysaccharide-induced iNOS synthesis in RAW 264.7 cells. Int. Immunopharmacol. 2011; 11(1):85-95.
Ishikawa Y, Iida H, Ishida H. The muscarinic acetylcholine receptor-stimulated increase in aquaporin-5 levels in the apical plasma membrane in rat parotid acinar cells is coupled with activation of nitric oxide/cGMP signal transduction. Mol. pharmacol. 2002; 61(6):1423-34.
Pui Ping C, Akhtar MN, Israf DA, Perimal EK, Sulaiman MR. Possible participation of ionotropic glutamate receptors and l-arginine-nitric oxide-cyclic guanosine monophosphateATP-sensitive K+channel pathway in the antinociceptive activity of cardamonin in acute pain animal models. Molecules. 2020; 25(22):5385.
Sherikar A, Dhavale R, Bhatia M. Vasorelaxant Effect of Novel Nitric Oxide-Hydrogen Sulfide Donor Chalcone in Isolated Rat Aorta: Involvement of cGMP Mediated sGC and Potassium Channel Activation. Curr. Mol. Pharmacol. 2020; 13(2):126-36.
Ooi L, Gigout S, Pettinger L, Gamper N. Triple cysteine module within M-type K+channels mediates reciprocal channel modulation by nitric oxide and reactive oxygen species. J. Neurosci. 2013; 33(14):6041-6.
Ocaña M, Cendán CM, Cobos EJ, Entrena JM, Baeyens JM. Potassium channels and pain: present realities and future opportunities. Eur. J. Pharmacol. 2004; 500(1-3):203-19.
Ortiz MI, Cariño-Cortés R, Castñeda-Hernández G. Participation of the opioid receptor–nitric oxide–cGMP–K+channe
l pathway in the peripheral antinociceptive effect of nalbuphine and buprenorphine in rats. Can. J. Physiol. Pharmacol. 2020; 98(11):753-62.
Du XN, Zhang X, Qi JL, An HL, Li JW, Wan YM, Fu Y, Gao HX, Gao ZB, Zhan Y, Zhang HL. Characteristics and molecular basis of celecoxib modulation on Kv7 potassium channels. Br. J. Pharmacol. 2011; 164(6):1722-37.
Judge SI, Bever Jr CT. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol. Ther. 2006; 111(1):224-59.
Krishnan AV, Lin CS, Park SB, Kiernan MC. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog. Neurobiol. 2009; 89(3):288-313.
Geng X, Du XN, Rusinova R, Liu BY, Li F, Zhang X, Chen XJ, Logothetis DE, Zhang HL. Specificity of Gβγ signaling depends on Gα subunit coupling with G-protein-sensitive K+channels. Pharmacology. 2009; 84(2):82-90.
Du X, Gamper N. Potassium channels in peripheral pain pathways: expression, function and therapeutic potential. Curr. Neuropharmacol. 2013; 11(6):621-40.
Abu Bakar NA. Antinociceptive and anti-inflammatory activities of 3-(2,5 dimethoxyphenyl)-1-(5 methylfuran-2-YL) prop-2-en-1 in mice. 2016.
Ortiz MI, Granados-Soto V, Castañeda-Hernández G. The NO–cGMP–K+channel pathway participates in the antinocice
ptive effect of diclofenac, but not of indomethacin. Pharmacol. Biochem. Behav. 2003; 76(1):187-95.
Lázaro-Ibáñez GG, Torres-López JE, Granados-Soto V. Participation of the nitric oxide–cyclic GMP–ATP-sensitive K+channel pathway in the antinociceptive action of ketorolac. Eur. J. Pharmacol. 2001; 426(1-2):39-44.
Lin YF. Potassium channels as molecular targets of endocannabinoids. Channels. 2021; 15(1):408-23.